What are the ACC/AHA (American College of Cardiology/American Heart Association) stage‑A to D management recommendations for an adult patient at risk for or with heart failure?

Heart Failure Stages and Management

ACC/AHA Staging System Overview

The ACC/AHA classification divides heart failure into four irreversible stages (A through D) that emphasize disease progression, with each stage requiring specific therapeutic interventions to reduce morbidity and mortality. 1, 2

The staging system is unidirectional—patients advance forward through stages but cannot revert to earlier stages, even with symptom resolution. 1, 2, 3 This contrasts with the NYHA functional classification, which fluctuates with treatment and assesses current symptom severity rather than disease progression. 2, 4

---

Stage A: At Risk for Heart Failure

Definition

Patients with risk factors for heart failure but no structural heart disease, no symptoms, and no elevated cardiac biomarkers. 1, 2

Risk Factors Include:

• Hypertension 1, 3
• Coronary artery disease 1, 3
• Diabetes mellitus 1, 3
• Obesity and metabolic syndrome 1, 3
• History of cardiotoxic drug or alcohol exposure 1, 3
• Family history of cardiomyopathy 1, 3
• History of rheumatic fever 3

Management Recommendations

Primary goal: Prevent development of structural heart disease through aggressive risk factor modification. 1, 3

Blood Pressure Control

• Target BP <130/80 mmHg using any antihypertensive agent 3
• Diuretics are superior to other antihypertensive classes for preventing heart failure progression 3

Pharmacologic Interventions

• ACE inhibitors or ARBs are appropriate for select patients with hypertension, diabetes, or atherosclerotic disease to prevent structural heart disease development 1, 3
• Statins for hyperlipidemia management in patients with atherosclerotic disease 3

Lifestyle Modifications

• Tobacco cessation with strong counseling (smoking strongly predicts incident heart failure) 3
• Weight management interventions for obesity 3
• Diabetes control (A1C levels directly correlate with heart failure risk) 3
• Alcohol moderation 2
• Regular exercise 2

---

Stage B: Pre-Heart Failure (Structural Disease Without Symptoms)

Definition

Patients with structural cardiac abnormalities (left ventricular hypertrophy, reduced ejection fraction, ventricular dilatation, asymptomatic valvular disease, prior myocardial infarction) who have never manifested symptoms. 1, 2

Management Recommendations

Primary goal: Prevent progression to symptomatic heart failure and reduce mortality through neurohormonal blockade. 1, 3

Cornerstone Pharmacotherapy for LVEF ≤40%

ACE Inhibitors (Class I, Level A)

• Mandatory for all patients with LVEF ≤40%, regardless of MI history 3
• Prevent symptomatic heart failure and reduce mortality 3

Beta-Blockers (Class I, Level B-R)

• Evidence-based beta-blockers required for all patients with LVEF ≤40% 3
• Prevent symptomatic heart failure development 3

ARBs

• Alternative for ACE inhibitor-intolerant patients, particularly post-MI with LVEF ≤40% 3

Statins (Class I, Level A)

• For patients with recent or remote MI or acute coronary syndrome 3
• Prevent symptomatic heart failure and cardiovascular events 3

Contraindicated Medications

• Thiazolidinediones are contraindicated in patients with LVEF <50% (increase heart failure risk and hospitalizations) 3
• Nondihydropyridine calcium channel blockers should be avoided in LVEF <50% (negative inotropic effects) 3

Additional Interventions

• All Stage A interventions continue 1, 2
• Implantable defibrillators in selected patients 1

---

Stage C: Symptomatic Heart Failure

Definition

Patients with current or past heart failure symptoms together with underlying structural heart disease. 1, 2 Once symptoms occur, patients remain Stage C permanently, regardless of subsequent symptom resolution. 2

Management Recommendations

Primary goal: Control symptoms, improve quality of life, reduce hospitalizations, and decrease mortality. 3, 4

Foundational Pharmacotherapy

All Stage A and B interventions continue 1, 2

Diuretics

• For all patients with evidence or history of volume overload 3
• Titrate to relieve congestion 3

SGLT2 Inhibitors

• Recommended for HFrEF 2

Aldosterone Receptor Antagonists

• For patients with NYHA class II-IV and LVEF ≤35% 3
• Monitor creatinine (≤2.5 mg/dL men, ≤2.0 mg/dL women) and potassium (<5.0 mEq/L) 1

Hydralazine-Isosorbide Dinitrate Combination (Level of Evidence: B)

• Particularly beneficial in African American patients 3
• Alternative for patients intolerant to ACE inhibitors/ARBs 3
• Reasonable addition for persistent symptoms despite ACEI and beta-blocker 1

Digoxin

• May be added for symptom management and reducing hospitalizations 3
• Does not reduce mortality 3

Lifestyle and Monitoring

Dietary Modifications

• Sodium restriction to 2-3 grams daily 3
• Individualized low-sodium diet 1

Exercise

• Exercise training recommended in stable patients to improve functional capacity 3

Sleep Disorders

• Screen and treat sleep apnea 3

Diagnostic Evaluation

Initial Laboratory Assessment 3

• Complete blood count
• Urinalysis
• Serum electrolytes, BUN, creatinine
• Fasting glucose, glycohemoglobin
• Lipid profile
• Liver function tests
• TSH

Cardiac Testing 3

• 12-lead ECG (if completely normal, systolic HF unlikely <10%) 4
• Chest X-ray (PA and lateral) 3
• 2D echocardiography with Doppler to assess LVEF, LV size, wall thickness, valve function 3

Biomarkers 3, 4

• BNP or NT-proBNP for diagnostic uncertainty, prognosis, and therapy optimization
• BNP <100 pg/mL or NT-proBNP <400 pg/mL: heart failure unlikely 4
• BNP 100-400 pg/mL or NT-proBNP 400-2000 pg/mL: diagnosis uncertain 4
• BNP >400 pg/mL or NT-proBNP >2000 pg/mL: heart failure likely 4

Coronary Evaluation

• Coronary angiography for patients with angina or significant ischemia unless not eligible for revascularization 3

---

Stage D: Advanced/Refractory Heart Failure

Definition

Patients with advanced structural disease and marked symptoms at rest despite maximal medical therapy, requiring specialized interventions. 1, 2 Common scenarios include frequent hospitalizations for decompensation or inability to be safely discharged. 1, 2

Management Recommendations

Primary goal: Palliate symptoms, improve quality of life, or bridge to definitive therapy. 1, 2

Advanced Therapeutic Options

Mechanical Circulatory Support

• LVAD or BiVAD as bridge to transplant or destination therapy 1, 2, 3
• Improved safety profile makes these increasingly common 5

Continuous Intravenous Inotropic Support

• For symptom relief in hospitalized patients 1, 2, 3

Cardiac Transplantation

• Evaluation recommended for eligible candidates 1, 2, 3

Palliative Care/Hospice

• Compassionate end-of-life care for patients not candidates for advanced therapies 1, 2, 3

Additional Considerations

• Procedures to facilitate fluid removal 1
• Experimental surgery or drugs 1

---

NYHA Functional Classification (Complementary to Staging)

The NYHA classification provides a dynamic, subjective assessment of current symptom severity that can improve or worsen with therapy, unlike the irreversible ACC/AHA stages. 2, 4

• Class I: No limitation; ordinary activity doesn't cause symptoms 1, 4
• Class II: Slight limitation; ordinary activity causes symptoms (7-15% mortality) 1, 4
• Class III: Marked limitation; less than ordinary activity causes symptoms (12-26% mortality) 1, 4
• Class IV: Unable to perform any activity without symptoms; symptoms at rest 1, 4

NYHA class remains an independent predictor of mortality despite its subjectivity and should be documented at baseline and reassessed throughout care. 2, 4

---

Critical Implementation Principles

• Therapeutic interventions before LV dysfunction or symptoms appear reduce population morbidity and mortality 1, 3
• Treatment strategies are anchored to the stage at which structural disease is first identified, ensuring early interventions are applied before irreversible remodeling 2
• Patients should be regularly reassessed as NYHA class may change with treatment, but ACC/AHA stage only advances forward 2, 4